HB2992 creates the Healing Opportunities through Psilocybin Equity Pilot Program Act, a comprehensive framework to regulate psilocybin in Illinois for therapeutic and adult-use purposes. The bill establishes an Illinois Psilocybin Advisory Board within the Department of Financial and Professional Regulation and assigns responsibilities across multiple agencies, including the Department of Public Health, Department of Agriculture, Illinois State Police, and Department of Revenue. During a multi-year program development period, those agencies would study research, develop rules, and prepare licensing and oversight systems before licenses could begin issuing on or before July 1 of the third year after enactment.
The bill would authorize several license types, including manufacturers, testing laboratories, service centers, and facilitators, and it sets detailed requirements for training, background checks, inspections, recordkeeping, labeling, packaging, dosage limits, and client safety procedures. It also creates a structured service model requiring preparation, administration, post-administration evaluation, and integration sessions, along with referral and screening requirements. The measure includes confidentiality protections, limited immunity for compliant licensees and their representatives, disciplinary authority, civil and criminal penalties for violations, and a statewide tracking system intended to prevent diversion and ensure product accountability.
HB2992 would also amend existing law in several areas. It adds psilocybin and psilocin to the Illinois Vehicle Code’s DUI provisions, makes conforming changes to the Freedom of Information Act, the State Finance Act, and the Illinois Independent Tax Tribunal Act, and limits home rule authority so local governments could not independently license or tax psilocybin activity. The bill imposes a 15% tax on psilocybin purchases beginning January 1, 2027, and directs revenue into newly created special funds for regulation and program administration. It also treats psilocybin-producing fungi as an agricultural crop for certain purposes and sets out rules for how psilocybin businesses may operate, including age restrictions and location limits.
The bill’s stated policy rationale is strongly supportive of regulated psilocybin access as a mental health and harm-reduction strategy. Its findings cite Illinois’s mental health crisis, veteran suicide, research on psilocybin-assisted therapy, and examples from Oregon and Colorado. The overall tone of the bill is expansive and reform-oriented, emphasizing equity, public health, culturally responsive services, and access for adults 21 and older. Because there is no committee transcript or recorded vote history provided, there is no documented legislative debate or formal vote sentiment in the supplied materials.
The main points of potential contention are likely to be the legalization and regulation of a psychedelic substance that remains restricted under federal law, the creation of a new tax and regulatory structure, and the bill’s broad preemption of local licensing and taxation authority. Other likely concerns include public safety, impaired driving, youth access, diversion to other states, and the scope of immunity and confidentiality protections for licensees and clients. Supporters would likely focus on mental health treatment access, harm reduction, and economic opportunity, while opponents may question medical efficacy, enforcement complexity, and the policy implications of state-sanctioned psilocybin services.
The bill would add a new chapter of state law governing psilocybin production, testing, sale, service, and taxation, while also amending the Freedom of Information Act, State Finance Act, Illinois Independent Tax Tribunal Act, and Illinois Vehicle Code. It would create new state funds, authorize new licenses and regulatory powers, and preempt local governments from independently licensing or taxing psilocybin businesses. It also expands DUI law to expressly include psilocybin and psilocin, and it establishes confidentiality and enforcement rules affecting agencies, licensees, clients, and related records.
The bill’s stated and apparent sentiment is strongly favorable toward regulated psilocybin access. Its findings and purpose sections frame the measure as a public health, equity, and harm-reduction response to mental health needs, with an emphasis on therapeutic use, research, and access for underserved communities. No committee transcript or vote record was provided, so there is no direct evidence of legislative debate, amendments, or formal support/opposition in the supplied materials.
The most likely areas of contention are the legalization of psilocybin services despite federal prohibition, the bill’s broad regulatory and tax scheme, and the decision to limit home rule authority over licensing and local taxation. Public safety issues—especially youth access, impaired driving, diversion, product testing, and oversight of facilitators and service centers—are also likely to draw scrutiny. Supporters are likely to emphasize mental health treatment, equity, and harm reduction, while critics may focus on drug policy concerns, implementation burden, and uncertainty around medical evidence and enforcement.